Metrics as of 10/17/2026, 09:25 AM (Berlin time), refresh in progress.
MoonLake Immunotherapeutics Stock
MoonLake Immunotherapeutics
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Jorge Santos da Silva
- Employees
- 130
- Market cap
- $813 M
- IPO
- 20/10/2020
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company focusing its efforts on the discovery and development of novel therapies. The primary focus of the company is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
MoonLake Immunotherapeutics stock: price history
1D
-6.9%
1W
-11.7%
1M
-23.4%
6M
-47.9%
YTD
-27.5%
1Y
+1.8%
2Y
-80.6%
5Y
-3.7%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~50% weaker price swings than usual
Ask the agents about MoonLake Immunotherapeutics
Analyst assessment of MoonLake Immunotherapeutics
PRICE TARGET LOW
US$50.00
CONSENSUS
US$50.00
MEDIAN
US$50.00
PRICE TARGET HIGH
US$50.00
0
STRONG BUY
15
BUY
2
HOLD
2
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 05/10/2026
MoonLake Immunotherapeutics stock metrics
P/E
-2.48
P/B
1.65
EV/EBITDA
-1.74
RETURN ON EQUITY
-14.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.24
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.3%
FLOAT SHARES
75,115,088
AVG. DAILY VOLUME (30D)
1,895,858
Insider transactions (SEC)
Reich Kristian
Reich Kristian
Reich Kristian
Reich Kristian
Reich Kristian
Institutional holders
Comparable stocks
Frequently asked questions about MoonLake Immunotherapeutics stock
What does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Jorge Santos da Silva, the company employs around 130 people.
The IPO was on 20/10/2020; the stock trades on NASDAQ under the ticker MLTX.
What do analysts say about MoonLake Immunotherapeutics stock?
19 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$50.00, ranging from US$50.00 to US$50.00, with a median of US$50.00.
This is an external assessment, not a statement by Market Jury.
When does MoonLake Immunotherapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -50% stronger than usual.
Does MoonLake Immunotherapeutics pay a dividend?
No, MoonLake Immunotherapeutics currently does not pay a dividend.
Which stocks are comparable to MoonLake Immunotherapeutics?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
How can I get MoonLake Immunotherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess MoonLake Immunotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.